Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GNFT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GNFT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Genfit S.A.

GNFT
Current price
3.66 USD -0.12 USD (-3.17%)
Last closed 3.87 USD
ISIN US3722791098
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 193 510 064 USD
Yield for 12 month -15.86 %
1Y
3Y
5Y
10Y
15Y
GNFT
21.11.2021 - 28.11.2021

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Address: Parc EurasantE, Loos, France, 59120

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

9.08 USD

P/E Ratio

96.75

Dividend Yield

Financials GNFT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GNFT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+78 837 476 USD

Last Year

+33 610 825 USD

Current Quarter

+71 895 279 USD

Last Quarter

+35 947 639 USD

Current Year

+78 484 483 USD

Last Year

+33 209 590 USD

Current Quarter

+70 879 835 USD

Last Quarter

+35 947 639 USD
EBITDA 4 693 000 USD
Operating Margin TTM -293.86 %
Price to Earnings 96.75
Return On Assets TTM 1.15 %
PEG Ratio
Return On Equity TTM 2.20 %
Wall Street Target Price 9.08 USD
Revenue TTM 70 692 000 USD
Book Value 1.39 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -50.50 %
Dividend Yield
Gross Profit TTM 70 692 000 USD
Earnings per share 0.040 USD
Diluted Eps TTM 0.040 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin 2.13 %

Stock Valuation GNFT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 96.75
Forward PE 7.27
Enterprise Value Revenue 2.17
Price Sales TTM 2.74
Enterprise Value EBITDA 17.47
Price Book MRQ 2.37

Technical Indicators GNFT

For 52 Weeks

2.55 USD 6.42 USD
50 Day MA 4.11 USD
Shares Short Prior Month 38 127
200 Day MA 4.20 USD
Short Ratio 8.52
Shares Short 37 726
Short Percent 0.080 %